The diagnostic and prognostic significance of delayed hypersensitivity skin testing in patients with urological cancer.
The responses to several skin test antigens of patients with bladder or prostatic cancer has been compared with responses of normal controls. All of the controls and all of the patients with prostatic cancer (irrespective of the stage of the tumour or the method of treatment) showed responses to dinitrochlorbenzene. 80% of all patients with bladder cancer responded to DNCB, but a highly significant number of patients with advanced disease showed no response. This test appears especially useful in predicting the prognosis in patients with bladder tumours and its routine use is recommended. Response to candida extract, streptokinase/streptodornase (SKSD) and purified protein derivative (PPD) were also studied. No conclusion could be drawn as to their value as a prognostic index.
D000368:Aged; D000951:Antigens, Neoplasm; D002175:Candida / Q000276:immunology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes; D010936:Plant Extracts; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis; D012882:Skin Tests; D013299:Streptodornase and Streptokinase; D014373:Tuberculin; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis; D014565:Urogenital Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; D009578:Nitrobenzenes; D010936:Plant Extracts; D014373:Tuberculin; D013299:Streptodornase and Streptokinase